Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewL-AP3
Discontinued Product
0273 has been discontinued.
View all Glutamate (Metabotropic) Group I Receptors products.
Description: Group I mGlu antagonist
Chemical Name: L(+)-2-Amino-3-phosphonopropionic acid
Biological Activity for L-AP3
Antagonist of mGlu receptor-mediated phosphoinositide responses; stimulatory effects also observed. Inhibitor of phosphoserine phosphatase (less potent than D-isomer (0272)).
Technical Data for L-AP3
| M. Wt | 169.07 |
| Storage | Store at RT |
| CAS Number | 23052-80-4 |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Product Datasheets for L-AP3
Certificate of Analysis is currently unavailable on-line.
Please contact Customer Service
Please contact Customer Service
References for L-AP3
References are publications that support the biological activity of the product.
Irving et al (1990) 1S,3R-ACPD stimulates and L-AP3 blocks Ca2+ mobilization in rat cerebellar neurons. Eur.J.Pharmacol. 186 363 PMID: 2289537
Mistry et al (1996) Stimulatory effects of the putative metabotropic glutamate receptor antagonist L-AP3 on phosphoinositide turnover. Br.J.Pharmacol. 117 1309 PMID: 8882630
Schoepp et al (1990) Stereoselectivity and mode of inhibition of phosphoinositide-coupled excitatory amino acid receptors by 2-amino-3-phosphonopropionic acid. Mol.Pharmacol. 38 222 PMID: 2166902
Schoepp and Conn (1993) Metabotropic glutamate receptors in brain function and pathology. TiPS 14 13 PMID: 7680175
View Related Products by Target
View Related Products by Product Action
View all Glutamate (Metabotropic) Group I Receptor Antagonists
Keywords: L-AP3, L-AP3 supplier, Glutamate, (Metabotropic), Group, I, Receptors, 0273, Tocris Bioscience
Citations for L-AP3
Citations are publications that use Tocris products.
Currently there are no citations for L-AP3.
Reviews for L-AP3
There are currently no reviews for this product. Be the first to review L-AP3 and earn rewards!
Have you used L-AP3?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Metabotropic Glutamate Receptors Scientific Review
Written by Francine Acher, this review discusses the pharmacology and therapeutic potential of mGlu receptors, and the compounds acting upon them; compounds available from Tocris are listed.
Addiction Poster
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Depression Poster
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Huntington's Disease Poster
Huntington's disease (HD) is a severe monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the effects of mutant huntingtin aggregation implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.